The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased ...

Overall, this suggests that the cumulative risk of breast cancer before age 55 for women taking estrogen/progestin is about 4 ...

Associations between hormone therapy and young-onset breast cancer (diagnosed at younger than 55 years) vary, according to a ...

Dr. Alicia Arnold and Dr. Priyanka Raval discuss first- and later-line treatment options for those with ER-positive, ...

STAMPEDE otherwise follows a line of randomized trials (e.g., MAST, TAXOMET, IMPROVE) that have failed to prove cancer ...

The addition of metformin “was generally well tolerated but did not result in the targeted benefit of a 20% reduction in risk of death in an unselected population,” the researchers wrote.

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Targeted cancer drugs known as CDK4/6 inhibitors have improved outcomes for patients with advanced or metastatic HR+/HER2- ...

A treatment for menopausal hot flushes has been approved by medicine watchdogs. UK regulators have become the first in the ...

Breast cancer survivors treated with radiation therapy have an 8% lower risk of developing Alzheimer’s disease, albeit only ...

Hot flashes are a menopausal hallmark: Up to 80 percent of women have them. But numerous lesser-known symptoms are also ...